We are Indivior.

Indivior is a global pharmaceutical company working to help change patients’ lives by pioneering life-transforming treatment for addiction and other serious mental illnesses.

Indivior manufactures and markets medicines for the treatment of moderate to severe opioid use disorder with a global portfolio in over 40 countries.

Indivior also markets medicine for the treatment of schizophrenia in adults in the United States and has a licensing agreement to bring this treatment to patients suffering from schizophrenia in Canada.

We continue to be an essential company helping in the fight against the opioid epidemic.

Indivior remains committed to discovering and developing new and effective treatments to help patients struggling with this disease.

Medication for opioid use disorder (MOUD) is increasingly recognized as an important part of addressing the opioid crisis. The medications Indivior provides play an essential role in treating opioid use disorder and addressing the opioid crisis.

Working with others, we are driving forward our understanding of addiction and other serious mental health diseases, working to create new science to help pave the way for an even deeper understanding of patient needs and treatment innovation.


Our Approach

Around the world, opioid use disorder is increasingly recognized as a treatable medical disease, and not a moral failing. Yet people suffering from addiction and mental health illnesses are still stereotyped and discounted, creating an environment where many remain under-diagnosed, under-treated and under-supported. They are often unaware of their treatment options, have limited access to treatment or simply don’t seek it out because they are afraid of being stigmatized.

The patient drives our decisions. Our guiding principles foster a culture of trust, innovation and a pioneering spirit. We work with the urgency required to achieve our Vision that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of addiction.

Until that day comes, we will continue to pioneer life-transforming treatment. We will continue to work with all stakeholders to shift public perceptions of these underserved patient populations, to humanize their suffering and to medicalize addiction as a chronic condition that must be treated in the same manner as other chronic diseases.